SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:uu-307551"
 

Sökning: onr:"swepub:oai:DiVA.org:uu-307551" > Lenalidomide-bendam...

  • Albertsson-Lindblad, AlexandraSkane Univ Hosp, Dept Oncol, SE-22185 Lund, Sweden. (författare)

Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma

  • Artikel/kapitelEngelska2016

Förlag, utgivningsår, omfång ...

  • American Society of Hematology,2016
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:uu-307551
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-307551URI
  • https://doi.org/10.1182/blood-2016-03-704023DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • For elderly patients with mantle cell lymphoma (MCL), there is no defined standard therapy. In this multicenter, open-label phase 1/2 trial, we evaluated the addition of lenalidomide (LEN) to rituximab-bendamustine (R-B) as first-line treatment for elderly patients with MCL. Patients >65 years with untreated MCL, stages II-IV were eligible for inclusion. Primary end points were maximally tolerable dose (MTD) of LEN and progression-free survival (PFS). Patients received 6 cycles every four weeks of L-B-R (L D1-14, B 90 mg/m(2) IV, days 1-2 and R 375 mg/m(2) IV, day 1) followed by single LEN (days 1-21, every four weeks, cycles 7-13). Fifty-one patients (median age 71 years) were enrolled from 2009 to 2013. In phase 1, the MTD of LEN was defined as 10 mg in cycles 2 through 6, and omitted in cycle 1. After 6 cycles, the complete remission rate (CRR) was 64%, and 36% were MRD negative. At a median follow-up time of 31 months, median PFS was 42 months and 3-year overall survival was 73%. Infection was the most common nonhematologic grade 3 to 5 event and occurred in 21 (42%) patients. Opportunistic infections occurred in 3 patients: 2 Pneumocystis carinii pneumonia and 1 cytomegalovirus retinitis. Second primary malignancies (SPM) were observed in 8 patients (16%). LEN could safely be combined with R-B when added from the second cycle in patients with MCL, and was associated with a high rate of CR and molecular remission. However, we observed a high degree of severe infections and an unexpected high number of SPMs, which may limit its use. This trial is registered at www.Clinicaltrials.gov as #NCT00963534.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Kolstad, ArneOslo Univ Hosp, Dept Oncol, Oslo, Norway. (författare)
  • Laurell, AnnaUniv Uppsala Hosp, Dept Oncol, Uppsala, Sweden.(Swepub:uu)annajohn (författare)
  • Raty, RiikkaHelsinki Univ Hosp, Dept Hematol, Helsinki, Finland. (författare)
  • Gronbaek, KirstenRigshosp, Dept Hematol, Copenhagen, Denmark. (författare)
  • Sundberg, JanSkane Univ Hosp, Dept Oncol, SE-22185 Lund, Sweden. (författare)
  • Pedersen, Lone BredoRigshosp, Dept Hematol, Copenhagen, Denmark. (författare)
  • Ralfkiaer, ElisabethRigshosp, Dept Pathol, Copenhagen, Denmark. (författare)
  • Karjalainen-Lindsberg, Marja-LiisaUniv Helsinki, Cent Hosp, Dept Pathol, Helsinki, Finland. (författare)
  • Sundström, ChristerUppsala universitet,Klinisk och experimentell patologi,Department of Pathology, Uppsala University Hospital, Uppsala, Sweden; and.,Rose-Marie Amini(Swepub:uu)chrisund (författare)
  • Ehinger, MatsUniv Lund Hosp, Dept Pathol Cytol, Lund, Sweden. (författare)
  • Geisler, ChristianRigshosp, Dept Hematol, Copenhagen, Denmark. (författare)
  • Jerkeman, MatsSkane Univ Hosp, Dept Oncol, SE-22185 Lund, Sweden. (författare)
  • Skane Univ Hosp, Dept Oncol, SE-22185 Lund, Sweden.Oslo Univ Hosp, Dept Oncol, Oslo, Norway. (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Blood: American Society of Hematology128:14, s. 1814-18200006-49711528-0020

Internetlänk

Hitta via bibliotek

  • Blood (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy